Patient characteristics at diagnosis (n = 113)
| . | Total (n = 113) . | HCT (n = 90) . | non-HCT (n = 23) . | P . |
|---|---|---|---|---|
| Age at diagnosis (y), median (range) | 61 (27-70) | 60 (27-69) | 65 (55-70) | <.001 |
| Gender | .058 | |||
| Male | 68 (60) | 50 (56) | 18 (78) | |
| Female | 45 (40) | 40 (44) | 5 (22) | |
| ATL subtype | .32 | |||
| Acute type | 79 (70) | 65 (72) | 14 (61) | |
| Lymphoma type | 34 (30) | 25 (28) | 9 (39) | |
| ECOG-PS | .046 | |||
| 0-1 | 83 (73) | 69 (77) | 14 (61) | |
| 2-4 | 24 (21) | 15 (17) | 9 (39) | |
| Unknown | 6 (5) | 6 (7) | 0 | |
| Compensated calcium concentration (mg/dL), median (range) | 9.7 (8.3-18.3) | 9.7 (8.3-18.3) | 9.7 (7.4-17.0) | .95 |
| ≥12 mg/dL | 14 (12) | 11 (12) | 3 (13) | 1.00 |
| CRP (mg/dL), median (range) | 0.36 (0.02-19.50) | 0.35 (0.02-19.50) | 0.38 (0.02-13.35) | .85 |
| ≥2.5 mg/dL | 23 (20) | 18 (20) | 5 (22) | 1.00 |
| sIL-2R (U/mL), median (range) | 12 476 (278-178 682) | 11 121 (278-178 682) | 17 042 (1,050-77 900) | .24 |
| >5000 U/mL | 83 (73) | 65 (72) | 18 (78) | .39 |
| mATL-PI | .079 | |||
| Low risk | 33 (29) | 30 (33) | 3 (13) | |
| Intermediate risk | 71 (63) | 52 (58) | 19 (83) | |
| High risk | 9 (8) | 8 (9) | 1 (4) |
| . | Total (n = 113) . | HCT (n = 90) . | non-HCT (n = 23) . | P . |
|---|---|---|---|---|
| Age at diagnosis (y), median (range) | 61 (27-70) | 60 (27-69) | 65 (55-70) | <.001 |
| Gender | .058 | |||
| Male | 68 (60) | 50 (56) | 18 (78) | |
| Female | 45 (40) | 40 (44) | 5 (22) | |
| ATL subtype | .32 | |||
| Acute type | 79 (70) | 65 (72) | 14 (61) | |
| Lymphoma type | 34 (30) | 25 (28) | 9 (39) | |
| ECOG-PS | .046 | |||
| 0-1 | 83 (73) | 69 (77) | 14 (61) | |
| 2-4 | 24 (21) | 15 (17) | 9 (39) | |
| Unknown | 6 (5) | 6 (7) | 0 | |
| Compensated calcium concentration (mg/dL), median (range) | 9.7 (8.3-18.3) | 9.7 (8.3-18.3) | 9.7 (7.4-17.0) | .95 |
| ≥12 mg/dL | 14 (12) | 11 (12) | 3 (13) | 1.00 |
| CRP (mg/dL), median (range) | 0.36 (0.02-19.50) | 0.35 (0.02-19.50) | 0.38 (0.02-13.35) | .85 |
| ≥2.5 mg/dL | 23 (20) | 18 (20) | 5 (22) | 1.00 |
| sIL-2R (U/mL), median (range) | 12 476 (278-178 682) | 11 121 (278-178 682) | 17 042 (1,050-77 900) | .24 |
| >5000 U/mL | 83 (73) | 65 (72) | 18 (78) | .39 |
| mATL-PI | .079 | |||
| Low risk | 33 (29) | 30 (33) | 3 (13) | |
| Intermediate risk | 71 (63) | 52 (58) | 19 (83) | |
| High risk | 9 (8) | 8 (9) | 1 (4) |
Patient characteristics at diagnosis were compared between the HCT group (n = 90) and the non-HCT group (n = 23).
CRP, C-reactive protein; sIL-2R, soluble interleukin-2 receptor.